Risperidone and escitalopram co-administration: A potential treatment of schizophrenia symptoms with less side effects

Abstract

The present study demonstrates that co-administration of risperidone and escitalopram may be used to treat positive and negative symptoms of schizophrenia and will allow to minimize the drugs' side effects.

Tetracarboxylic acids on a thiacalixarene scaffold: synthesis and binding of dopamine hydrochloride

“…Moreover, they differ favorably from the classical calixarenes platform by the possibility of obtaining various spatial isomers with given position of binding groups relative to the cyclophane platform by using the template synthesis method. 31 It should be noted that at this time there are no data on host molecules for dopamine on the basis of thiacalix [4]arene. However, one paper was published where a thiacalix [4]arene derivative functionalized by a dopamine fragment in the stereochemical conformation of 1,3-alternate was proposed for the electrochemical determination of dopamine.…”

“…It plays a key role during various physiological processes, such as adaptation to stress, and serves as an important part of the brain reward system. 1,2 At present, excess dopamine is associated with such diseases as schizophrenia (its positive symptoms), restless legs syndrome, myofascial syndrome, tics, and deficiency with parkinsonism, depressive states, and dementia, [3][4][5][6][7][8] and therefore the design of compounds that selectively bind dopamine is essential.…”

“…Currently, various synthetic compounds capable of selective binding with dopamine through multiple non-covalent interactions, such as electrostatic interactions, hydrogen bonding, p-p-stacking, and hydrophobic forces, have been proposed as host molecules. The organophosphorus compounds, 9 calix[n]arenes (n = 4, 5, 6), [10][11][12][13][14][15][16] calix [4]resorcinarenes, 17 and pillar [5]arenes 18 with acidic, 10,12 quinone 11 and amide 8 groups, and charged fragments 14,18 as binding sites, show complexation ability toward dopamine.…”

Neurobiological Role of Hypocretin in Regulation of Psychiatric Disorders

“…This disease has been managed by using pharmacological means including compounds that interact with monoaminergic transmission [47][48][49][50]. Recent data have suggested the putative role of hypocretin in modulation of schizophrenia [36].…”

Extrapyramidal Symptoms in Patients Treated with Antipsychotic Drugs

“…Akathisia occurs in 11% of patients treated with cariprazine [19]. SGAs such as risperidone, olanzapine and quetiapine cause cognitive impairment, because they inhibit dopamine/serotonin release, above all in the prefrontal cortex [20]. Recently developed SGAs such as aripiprazole and cariparzine have a different mechanism of action; they act as partial agonist at the D2 receptor.…”